Search

Displaying results 1561 - 1570 of 10000 in total
  1. Drug

    Basiliximab

    go.drugbank.com/drugs/DB00074
    ApprovedInvestigational

    A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also … It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes

    Products: SIMULECT FOR INJECTION 20 mg/vial, SIMULECT® LIOFILIZADO PARA INYECCION 20 MG/VIAL
  2. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.

    Products: Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection
  3. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. … [L13880,L13883] It has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and efficacy.[A203255] Lymecycline was initially discovered in 1961.

    Synonyms: Tetracycline-L-methylenelysine, Tetracycline-L-methylene lysineProducts: CycloPel 300 mg Kapseln, TETRALYSAL® CAPSULAS 300 MG
  4. Drug

    Tioguanine

    go.drugbank.com/drugs/DB00352
    ApprovedInvestigational

    An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

    Synonyms: TG, 6-TGProducts: THIOGUANINE TABLETAS 40 MG, Thioguanin "Aspen" 40 mg Tabletten
  5. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. … Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).

  6. Drug

    Sucralose

    go.drugbank.com/drugs/DB15049
    Investigational

    Sucralose is an artificial sweetener used as a sugar substitute.

    Categories: Compounds used in a research, industrial, or household settingProducts: DE-LİGHT 6.05 MG TABLET, 100 ADET, DE-LİGHT 6.05 MG TABLET, 300 ADET
  7. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: SOTYKTU 6 mg film coated tablets, SOTYKTU® 6MG TABLETAS RECUBIERTAS
  8. Drug

    Praziquantel

    go.drugbank.com/drugs/DB01058
    ApprovedInvestigationalVet approved

    Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. … Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: DISTOCIDE TABLET 600 mg
  9. Drug

    Ilaprazole

    go.drugbank.com/drugs/DB11964
    Investigational

    Ilaprazole has been investigated in Helicobacter Infections.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: NOLTEC 10 MG GASTRO-REZİSTAN TABLET, 7 ADET, NOLTEC 10 MG GASTRO-REZİSTAN TABLET, 28 ADET
  10. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846]. … Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295].

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InducersProducts: ERLEADA ®TABLETAS RECUBIERTAS 60 MG